GlobeNewswire Inc | Jan 5, 2022 08:00AM EST

January 05, 2022

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Companys progress at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday, January 12, 2022 at 9:00 a.m. ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Companys website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for 30 days.

About Black DiamondBlack Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Companys proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

ContactsFor Investors:Julie Seidelinvestors@bdtx.com

For Media:Kathy Vincent(310) 403-8951media@bdtx.com